Complementary and alternative medicine (CAM) supplements in cancer outpatients: analyses of usage and of interaction risks with cancer treatment

GND
1277655677
ORCID
0000-0002-5429-2008
Affiliation
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
Wolf, Clemens P. J. G.;
GND
1018243313
Affiliation
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Pneumologie, Universitätsklinikum Jena, Jena, Germany
Rachow, Tobias;
GND
129357685
Affiliation
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Konservative Tagesklinik des UniversitätsTumorCentrums (UTC), Universitätsklinikum Jena, Jena, Germany
Ernst, Thomas;
GND
1107039339
Affiliation
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
Hochhaus, Andreas;
GND
123786363
Affiliation
Onkologische Kooperation Harz, Goslar, Germany
Zomorodbakhsch, Bijan;
GND
1270828711
Affiliation
Klinik für Urologie, Universitätsklinikum Jena, Jena, Germany
Foller, Susan;
GND
1312100443
Affiliation
Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin, Universitätsklinikum Jena, Jena, Germany
Rengsberger, Matthias;
GND
123079640
Affiliation
Apotheke des Universitätsklinikums, Universitätsklinikum Jena, Jena, Germany
Hartmann, Michael;
GND
13402012X
Affiliation
Klinik für Innere Medizin II, Hämatologie und Internistische Onkologie, Integrative Onkologie, Universitätsklinikum Jena, Jena, Germany
Huebner, Jutta

Abstract Purpose The aim of our study was to analyze the use of complementary and alternative medicine (CAM) supplements, identify possible predictors, and analyze and compile potential interactions of CAM supplements with conventional cancer therapy. Methods We included outpatient cancer patients treated at a German university hospital in March or April 2020. Information was obtained from questionnaires and patient records. CAM–drug interactions were identified based on literature research for each active ingredient of the supplements consumed by the patients. Results 37.4% of a total of 115 patients consumed CAM supplements. Potential interactions with conventional cancer treatment were identified in 51.2% of these patients. All types of CAM supplements were revealed to be a potential source for interactions: vitamins, minerals, food and plant extracts, and other processed CAM substances. Younger age (< 62 years) ( p  = 0.020, φc = 0.229) and duration of individual cancer history of more than 1 year ( p  = 0.006, φc = 0.264) were associated with increased likelihood of CAM supplement use. A wide range of different CAM supplement interactions were reviewed: effects of antioxidants, cytochrome (CYP) interactions, and specific agonistic or antagonistic effects with cancer treatment. Conclusion The interaction risks of conventional cancer therapy with over-the-counter CAM supplements seem to be underestimated. Supplements without medical indication, as well as overdoses, should be avoided, especially in cancer patients. To increase patient safety, physicians should address the risks of interactions in physician–patient communication, document the use of CAM supplements in patient records, and check for interactions.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © The Author(s) 2021

Use and reproduction: